.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC05_Ustekinumab.Ustekinumab

Information

Ustekinumab is a human monoclonal antibody targeting interleukin-12 (IL-12) and interleukin-23 (IL-23), used primarily for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is approved for clinical use in many countries and is considered a biologic therapy for immune-mediated inflammatory disorders.

Pharmacokinetics

Population pharmacokinetic parameters for ustekinumab in adults with moderate to severe plaque psoriasis after subcutaneous administration.

References

1. Feagan, BG, et al., & Rutgeerts, P (2016). Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. The New England journal of medicine 375(20) 1946–1960. DOI:10.1056/NEJMoa1602773 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27959607

2. Xu, Y, et al., & Zhou, H (2020). Population Pharmacokinetics and Exposure-Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative Colitis. Journal of clinical pharmacology 60(7) 889–902. DOI:10.1002/jcph.1582 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32026499

3. Zhu, YW, et al., & Zhou, H (2010). Population pharmacokinetics of ustekinumab in patients with active psoriatic arthritis. International journal of clinical pharmacology and therapeutics 48(12) 830–846. DOI:10.5414/cpp48830 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21084039

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)